Bridge to Life
Bridge to Life develops organ preservation technologies, including its flagship Belzer UW® solutions and the VitaSmart™ machine perfusion system.
Secondary Market Price
How Bridge to Life Measures Up
To help you manage your Bridge to Life equity, Prospect has run the company through our machine learning model.
Prospect Rating
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Bridge to Life's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Bridge to Life Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Bridge to Life's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Bridge to Life is a global company that develops, manufactures, and distributes organ preservation and perfusion solutions for transplantation. Its current activities involve providing products like Belzer UW® Cold Storage Solution and Belzer MPS® UW Machine Perfusion Solution to organ procurement organizations and transplant centers. The company is also advancing machine perfusion technology with its VitaSmart™ Hypothermic Oxygenated Machine Perfusion System. While a detailed chronological history is not specified, the company is established within the organ transplantation field, initially known for its Belzer UW® solutions before expanding its portfolio to include machine perfusion systems and related products.
Looking forward, Bridge to Life is focused on advancing organ delivery and preservation technologies to increase the quantity and quality of donor organs. A key part of this strategy is the ongoing Bridge to HOPE clinical trial for its VitaSmart™ system, which is pending regulatory clearance in the United States. Recent company announcements include receiving FDA 510(k) clearance for multi-sourced Belzer UW® and MPS® solutions, which expanded labeling for use across all abdominal organs. The company also appointed David Castiglioni as Chief Commercial Officer to lead global commercial operations and the eventual U.S. commercialization of VitaSmart™.
- Perceptive Advisors
- Peter Maag
- Founder, CEO Stevan Schweighardt
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Bridge to Life worth joining?
Deciding whether to join a startup like Bridge to Life depends on your personal career goals and assessment of the company's potential. Tools like Prospect can help you understand and model the value of the equity compensation being offered, which is a critical part of the decision.
What should I do with my Bridge to Life stock?
Managing private company stock involves complex decisions around taxes, timing, and valuation that depend on your personal financial situation. Platforms like Prospect provide personalized strategies for exercising options and managing shares to maximize their post-tax value.
Can you sell Bridge to Life stock?
Selling stock in a private company like Bridge to Life is typically possible during specific liquidity events like tender offers or via secondary markets. Platforms such as Prospect offer tools to help you decide how much to sell and which shares are most tax-efficient to offload.
How can I find the value of my Bridge to Life stock?
Since Bridge to Life is a private company, its stock isn't publicly traded, making valuation complex. You can use specialized platforms like Prospect, which employ predictive models to help forecast your equity's potential future value.
What is Bridge to Life's equity worth?
The total equity valuation of a private company like Bridge to Life is not public information and is typically determined during private funding rounds. To understand what your personal equity stake could be worth, you can use forecasting tools like those offered by Prospect to model various growth scenarios.
What is Bridge to Life's stock ticker symbol?
Private companies like Bridge to Life do not have a stock ticker symbol as they are not listed on a public stock exchange. A ticker is only assigned if and when a company completes an Initial Public Offering (IPO).
Can I buy or sell Bridge to Life stock?
As a private company, buying Bridge to Life stock is generally restricted to employees exercising options or accredited investors in funding rounds. Selling is also limited, typically to company-approved windows, but platforms like Prospect can help you prepare for and optimize these opportunities.
What is the criteria to buy or invest in Bridge to Life stock?
Investing in a private company like Bridge to Life is typically limited to employees receiving equity compensation or accredited investors participating in private funding rounds. If you are an employee with equity, you can use a platform like Prospect to manage your holdings and optimize their value.
